Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated)
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated)
- DrugBank Accession Number
- DB14445
- Background
A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen". This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. Upon re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it was previously exposed to.
There are two basic types of vaccines available: inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV). Inactivated vaccines contain a virus particle that has been grown in media and then subsequently killed, or inactivated, through exposure to heat or chemicals such as formaldehyde 3. Inactivated virus cannot replicate, and therefore cannot cause disease from infection, even in immunocompromised individuals. In contrast, live vaccines are produced from "wild-type" or disease-causing viruses that have been attenuated, or weakened, through various laboratory techniques. Live vaccines maintain their replicative ability.
- Type
- Biotech
- Groups
- Approved
- Biologic Classification
- Vaccines
Inactivated - Synonyms
- Not Available
Pharmacology
- Indication
Not Available
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset- Contraindications & Blackbox Warnings
Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbatacept The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Abatacept. Acetylsalicylic acid The risk or severity of adverse effects can be increased when Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) is combined with Acetylsalicylic acid. Adalimumab The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Adalimumab. Aldesleukin The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Aldesleukin. Alefacept The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Alefacept. Alemtuzumab The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Alemtuzumab. Altretamine The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Altretamine. Aminosalicylic acid The risk or severity of adverse effects can be increased when Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) is combined with Aminosalicylic acid. Amsacrine The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Amsacrine. Anakinra The therapeutic efficacy of Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) can be decreased when used in combination with Anakinra. 
Improve patient outcomesBuild effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.Learn more - Food Interactions
- Not Available
Products
Comprehensive & structured drug product infoFrom application numbers to product codes, connect different identifiers through our commercial datasets.Easily connect various identifiers back to our datasets- Active Moieties
Name Kind UNII CAS InChI Key Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) hemagglutinin 3Q80689L6F Not Available Not applicable - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Fluarix 2011/2012 Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) (15 ug/0.5mL) Suspension Intramuscular GlaxoSmithKline Biologicals SA 2011-07-01 2011-07-01 US 
Fluzone Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) (15 ug/0.5mL) Injection, suspension Intramuscular Sanofi Pasteur Limited 2011-07-01 2012-06-30 US Fluzone Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) (15 ug/0.5mL) Injection, suspension Intramuscular Sanofi Pasteur Limited 2010-07-23 2011-06-30 US Fluzone Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) (7.5 ug/0.25mL) + Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated) (7.5 ug/0.25mL) + Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) (7.5 ug/0.25mL) Injection, suspension Intramuscular Sanofi Pasteur Limited 2011-07-01 2012-06-30 US Fluzone Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) (15 ug/0.5mL) Injection, suspension Intramuscular Physicians Total Care, Inc. 2010-09-21 2011-06-30 US Fluzone Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) (15 ug/0.5mL) Injection, suspension Intramuscular Sanofi Pasteur Limited 2011-07-01 2012-06-30 US Fluzone Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) (15 ug/0.5mL) Injection, suspension Intramuscular Sanofi Pasteur Limited 2010-07-23 2011-06-30 US Fluzone Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated) (15 ug/0.5mL) + Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) (15 ug/0.5mL) Injection, suspension Intramuscular Physicians Total Care, Inc. 2010-09-16 2011-06-30 US FLUZONE High-Dose Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) (60 ug/0.5mL) + Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated) (60 ug/0.5mL) + Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) (60 ug/0.5mL) Injection, suspension Intramuscular Sanofi Pasteur Limited 2011-07-01 2012-06-30 US FLUZONE High-Dose Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) (60 ug/0.5mL) + Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (formaldehyde inactivated) (60 ug/0.5mL) + Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) (60 ug/0.5mL) Injection, suspension Intramuscular Sanofi Pasteur Limited 2010-07-23 2011-06-30 US
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 3Q2OMA2GNK
- CAS number
- Not Available
References
- General References
- Not Available
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Active Not Recruiting Basic Science Flu caused by Influenza 2 4 Active Not Recruiting Basic Science Flu caused by Influenza / Healthy Adults / Hepatitis A / Salmonella Typhi Infection 1 4 Active Not Recruiting Prevention Flu caused by Influenza 1 4 Active Not Recruiting Treatment Flu caused by Influenza 1 4 Completed Basic Science Cytomegalovirus (CMV) Infection / Flu caused by Influenza 1 4 Completed Basic Science Flu caused by Influenza 12 4 Completed Basic Science Flu Vaccine 1 4 Completed Basic Science Immune Response to Influenza Vaccine / Influenza A Virus Infection / Influenza B Virus Infection 1 4 Completed Basic Science MELAS Syndrome 1 4 Completed Basic Science Rheumatoid Arthritis 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Suspension Intramuscular Injection, suspension Intramuscular Injection, suspension Intradermal - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
Drug created on July 05, 2018 18:03 / Updated on June 12, 2020 16:53